NCT02651610View on ClinicalTrials.gov

Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer

PHASE2/PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2015

Primary Completion Date

December 31, 2017

Study Completion Date

June 30, 2018

Conditions
Metastatic Breast Cancer
Interventions
BIOLOGICAL

Bavituximab

Biological: bavituximab

DRUG

Taxane

Drug: Taxane Other names: Paclitaxel. Taxotere, Taxotere, Docecad, Taxol

Trial Locations (2)

60487

Peregrine Pharmaceuticals Investigational Site, Tinley Park

93309

Peregrine Pharmaceuticals Investigational Site, Bakersfield

Sponsors
All Listed Sponsors
lead

Peregrine Pharmaceuticals

INDUSTRY